Infographic – Can Eli Lilly turn up the competitive heat in diabetes?

US approval for Eli Lilly's Trulicity (dulaglutide) – granted by the FDA last week – represents a significant event in the $3-billion market for GLP-1 agonists, an important class of diabetic medication.

This market has to date been dominated by Novo Nordisk's Victoza, which generated sales of $2 billion in 2013 and currently commands a 67 percent share of the US GLP-1 segment.

Trulicity represents a commercial threat to Victoza on two counts; it is the first rival GLP-1 agonist to demonstrate non-inferiority to Novo Nordisk's product in terms of efficacy and safety and is dosed once-weekly, versus Victoza's once-daily administration.

Although analysts at Bloomberg Industries suggested last week that Victoza and Trulicity will dominate the GLP-1 agonist market through to the end of the decade, consensus forecasts continue to provide a large advantage for Novo Nordisk's product.

Pricing and payer access may prove critical. Trulicity provides pharmacy benefit managers additional leverage to negotiate greater discounting in return for exclusive formulary recommendation, while Eli Lilly now commands a presence within each of the 'oral' and insulin drug classes, a potential advantage in negotiating access argue analysts.

See also:

ViewPoints: Sanofi touts oral GLP-1 opportunity, but competition from Novo Nordisk will be difficult to overcome

ViewPoints: Will breadth of Eli Lilly's portfolio prove crucial as diabetes pricing pressure intensifies?

Spotlight On: GlaxoSmithKline makes return to diabetes market, but finds few familiarities

Physician Views Poll Results: Endocrinologists favour Victoza over dulaglutide – but only other key findings ahead of the ADA meeting

Physician Views Poll Results: Weight-loss profile will be key to driving uptake of Eli Lilly's dulaglutide, say endocrinologists

ViewPoints: ADA Preview - Eli Lilly's dulaglutide fails to match Victoza's weight-loss profile – can it still compete?

To read more List articles, click here.